NuSirt Biopharma

CompanyUnited States

NuSirt Biopharma develops 2 assets, the furthest in phase 2 (NS-0200 in hypertension). Mostly small molecule; based in the United States.

2
Assets
Furthest stage
Phase 2
4
Trials
4
Signals

Pipeline

2
  • NS-0100

    Synergistic combination of leucine and metformin activating sirtuin and AMPK pathways to improve glycemic control.

    Phase 2, no development reported, Small molecule, type 2 diabetes

  • NS-0200

    Phase 2, hypertension, metabolic dysfunction-associated steatotic liver disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials4
  • Signals7
  • Similar companies6

Intelligence